394 related articles for article (PubMed ID: 21410684)
1. Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH).
Ventura S; Oliver Vl; White CW; Xie JH; Haynes JM; Exintaris B
Br J Pharmacol; 2011 Jul; 163(5):891-907. PubMed ID: 21410684
[TBL] [Abstract][Full Text] [Related]
2. Translational pharmacology in aging men with benign prostatic hyperplasia: molecular and clinical approaches to alpha1-adrenoceptors.
Kojima Y; Kubota Y; Sasaki S; Hayashi Y; Kohri K
Curr Aging Sci; 2009 Dec; 2(3):223-39. PubMed ID: 20021417
[TBL] [Abstract][Full Text] [Related]
3. The role of combination medical therapy in benign prostatic hyperplasia.
Greco KA; McVary KT
Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
[TBL] [Abstract][Full Text] [Related]
4. Adrenoceptor pharmacology: urogenital applications.
Ruffolo RR; Hieble JP
Eur Urol; 1999; 36 Suppl 1():17-22. PubMed ID: 10393468
[TBL] [Abstract][Full Text] [Related]
5. Benign prostatic hyperplasia - progress in pathophysiology and management.
Dobrek Ł; Thor PJ
Pol Merkur Lekarski; 2015 Nov; 39(233):263-70. PubMed ID: 26637089
[TBL] [Abstract][Full Text] [Related]
6. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.
Gacci M; Eardley I; Giuliano F; Hatzichristou D; Kaplan SA; Maggi M; McVary KT; Mirone V; Porst H; Roehrborn CG
Eur Urol; 2011 Oct; 60(4):809-25. PubMed ID: 21726934
[TBL] [Abstract][Full Text] [Related]
7. Regulation of prostatic smooth muscle contractility by intracellular second messengers: implications for the conservative treatment of benign prostatic hyperplasia.
Eckert RE; Schreier U; Drescher P; Madsen PO; Derouet H; Becht E; Steffens J; Ziegler M
Urol Int; 1995; 54(1):6-21. PubMed ID: 7539557
[TBL] [Abstract][Full Text] [Related]
8. Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia.
Logan YT; Belgeri MT
Am J Geriatr Pharmacother; 2005 Jun; 3(2):103-14. PubMed ID: 16129387
[TBL] [Abstract][Full Text] [Related]
9. The long-term cost effectiveness of treatments for benign prostatic hyperplasia.
DiSantostefano RL; Biddle AK; Lavelle JP
Pharmacoeconomics; 2006; 24(2):171-91. PubMed ID: 16460137
[TBL] [Abstract][Full Text] [Related]
10. Terazosin. A pharmacoeconomic evaluation of its use in benign prostatic hyperplasia.
Plosker GL; Goa KL
Pharmacoeconomics; 1997 Feb; 11(2):184-97. PubMed ID: 10165827
[TBL] [Abstract][Full Text] [Related]
11. Alpha-adrenoceptor antagonists in the treatment of benign prostatic hyperplasia.
Cooper KL; McKiernan JM; Kaplan SA
Drugs; 1999 Jan; 57(1):9-17. PubMed ID: 9951948
[TBL] [Abstract][Full Text] [Related]
12. Comparative Effectiveness of Newer Medications for Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis.
Dahm P; Brasure M; MacDonald R; Olson CM; Nelson VA; Fink HA; Rwabasonga B; Risk MC; Wilt TJ
Eur Urol; 2017 Apr; 71(4):570-581. PubMed ID: 27717522
[TBL] [Abstract][Full Text] [Related]
13. Animal models for benign prostatic hyperplasia.
Hieble JP
Handb Exp Pharmacol; 2011; (202):69-79. PubMed ID: 21290222
[TBL] [Abstract][Full Text] [Related]
14. Apoptotic Pathways Linked to Endocrine System as Potential Therapeutic Targets for Benign Prostatic Hyperplasia.
Minutoli L; Rinaldi M; Marini H; Irrera N; Crea G; Lorenzini C; Puzzolo D; Valenti A; Pisani A; Adamo EB; Altavilla D; Squadrito F; Micali A
Int J Mol Sci; 2016 Aug; 17(8):. PubMed ID: 27529214
[TBL] [Abstract][Full Text] [Related]
15. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: sexual function.
Lowe FC
BJU Int; 2005 Jun; 95 Suppl 4():12-8. PubMed ID: 15871731
[TBL] [Abstract][Full Text] [Related]
16. Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) - focus on the UK.
Speakman M; Kirby R; Doyle S; Ioannou C
BJU Int; 2015 Apr; 115(4):508-19. PubMed ID: 24656222
[TBL] [Abstract][Full Text] [Related]
17. The diagnosis and treatment of lower urinary tract symptoms due to benign prostatic hyperplasia with α-blockers: focus on silodosin.
Fonseca J; Martins da Silva C
Clin Drug Investig; 2015 Feb; 35 Suppl 1():7-18. PubMed ID: 25708606
[TBL] [Abstract][Full Text] [Related]
18. New strategies for inhibition of non-adrenergic prostate smooth muscle contraction by pharmacologic intervention.
Yu Q; Gratzke C; Wang Y; Wang X; Li B; Strittmatter F; Herlemann A; Wang R; Tamalunas A; Waidelich R; Stief CG; Hennenberg M
Prostate; 2019 May; 79(7):746-756. PubMed ID: 30811062
[TBL] [Abstract][Full Text] [Related]
19. The role of muscarinic receptor subtypes on carbachol-induced contraction of normal human detrusor and overactive detrusor associated with benign prostatic hyperplasia.
Yamanishi T; Kaga K; Fuse M; Shibata C; Kamai T; Uchiyama T
J Pharmacol Sci; 2015 Jun; 128(2):65-70. PubMed ID: 26084660
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Side Effects of Drugs Commonly Used for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia.
Yu ZJ; Yan HL; Xu FH; Chao HC; Deng LH; Xu XD; Huang JB; Zeng T
Front Pharmacol; 2020; 11():658. PubMed ID: 32457631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
